title: Scoring oral mucositis.
abstract: Oral mucositis is a common, dose limiting and potentially serious complication of both radiation and chemotherapy. Both these therapies are non-specific, interfering with the cellular homeostasis of both malignant and normal host cells. An important effect is the loss of the rapidly proliferating epithelial cells in the oral cavity, gut and in the bone marrow. Within the mouth, the loss of these cells leads to mucosal atrophy, necrosis and ulceration. Although post-treatment healing is generally uneventful, severe mucositis can be life threatening, especially if complicated by dehydration or secondary infection. Accurate and reproducible evaluation of oral mucositis is important in order to monitor patient toxicity during therapy, to document the toxicity of conventional therapy and to critically assess the effects of alternative therapies. A number of oral toxicity scoring systems have been described, but direct comparisons have rarely been undertaken and little data exist regarding inter- and intra-user reliability. This paper reviews a number of oral mucositis scoring systems that are commonly used and will also discuss, briefly, the biological basis of its development and management.
authors.affiliation: Toronto-Sunnybrook Regional Cancer Centre, University of Toronto, Canada.
authors.forename: W
authors.initials: W
authors.lastname: Parulekar
authors.forename: R
authors.initials: R
authors.lastname: Mackenzie
authors.forename: G
authors.initials: G
authors.lastname: Bjarnason
authors.forename: R C
authors.initials: RC
authors.lastname: Jordan
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D006801:Humans; D009061:Mouth Mucosa / Q000473:pathology; D011878:Radiotherapy / Q000009:adverse effects; D012720:Severity of Illness Index; D013280:Stomatitis / Q000209:etiology / Q000473:pathology* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents